143 related articles for article (PubMed ID: 17390027)
41. Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.
Carbó N; López-Soriano J; Tarragó T; González O; Llovera M; López-Soriano FJ; Argilés JM
Cancer Lett; 1997 May; 115(1):113-8. PubMed ID: 9097986
[TBL] [Abstract][Full Text] [Related]
42. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
43. Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia.
Englund DA; Jolliffe AM; Hanson GJ; Aversa Z; Zhang X; Jiang X; White TA; Zhang L; Monroe DG; Robbins PD; Niedernhofer LJ; Kamenecka TM; Khosla S; LeBrasseur NK
JCI Insight; 2024 Jan; 9(2):. PubMed ID: 38051584
[TBL] [Abstract][Full Text] [Related]
44. Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.
Busquets S; Toledo M; Marmonti E; Orpí M; Capdevila E; Betancourt A; López-Soriano FJ; Argilés JM
Oncol Lett; 2012 Jan; 3(1):185-189. PubMed ID: 22740878
[TBL] [Abstract][Full Text] [Related]
45. Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis.
Liu H; Li L; Zou J; Zhou T; Wang B; Sun H; Yu S
BMC Complement Altern Med; 2019 Oct; 19(1):267. PubMed ID: 31615487
[TBL] [Abstract][Full Text] [Related]
46. β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.
Aversa Z; Bonetto A; Costelli P; Minero VG; Penna F; Baccino FM; Lucia S; Rossi Fanelli F; Muscaritoli M
Int J Oncol; 2011 Mar; 38(3):713-20. PubMed ID: 21184031
[TBL] [Abstract][Full Text] [Related]
47. Curcumin Targeting NF-
Zhang J; Zheng J; Chen H; Li X; Ye C; Zhang F; Zhang Z; Yao Q; Guo Y
Mediators Inflamm; 2022; 2022():2567150. PubMed ID: 35132306
[TBL] [Abstract][Full Text] [Related]
48. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats.
Temparis S; Asensi M; Taillandier D; Aurousseau E; Larbaud D; Obled A; Béchet D; Ferrara M; Estrela JM; Attaix D
Cancer Res; 1994 Nov; 54(21):5568-73. PubMed ID: 7923198
[TBL] [Abstract][Full Text] [Related]
49. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma.
Baracos VE; DeVivo C; Hoyle DH; Goldberg AL
Am J Physiol; 1995 May; 268(5 Pt 1):E996-1006. PubMed ID: 7539218
[TBL] [Abstract][Full Text] [Related]
50. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats.
Llovera M; García-Martínez C; Agell N; Marzábal M; López-Soriano FJ; Argilés JM
FEBS Lett; 1994 Feb; 338(3):311-8. PubMed ID: 8307200
[TBL] [Abstract][Full Text] [Related]
51. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
52. Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
Trobec K; Palus S; Tschirner A; von Haehling S; Doehner W; Lainscak M; Anker SD; Springer J
Nutrition; 2014 Sep; 30(9):1069-75. PubMed ID: 24976415
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130).
Costelli P; Llovera M; Carbó N; García-Martínez C; López-Sorianoq FJ; Argilés JM
Cancer Lett; 1995 Aug; 95(1-2):33-8. PubMed ID: 7656241
[TBL] [Abstract][Full Text] [Related]
54. Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.
Vaughan VC; Sullivan-Gunn M; Hinch E; Martin P; Lewandowski PA
PLoS One; 2012; 7(9):e45900. PubMed ID: 23029301
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats.
Figueras M; Busquets S; Carbó N; Barreiro E; Almendro V; Argilés JM; López-Soriano FJ
FEBS Lett; 2004 Jul; 569(1-3):201-6. PubMed ID: 15225634
[TBL] [Abstract][Full Text] [Related]
56. IGF-1 is downregulated in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bossola M; Penna F; Reffo P; Bonetto A; Busquets S; Bonelli G; Lopez-Soriano FJ; Doglietto GB; Argilés JM; Baccino FM; Rossi Fanelli F
Am J Physiol Regul Integr Comp Physiol; 2006 Sep; 291(3):R674-83. PubMed ID: 16614058
[TBL] [Abstract][Full Text] [Related]
57. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.
Wyke SM; Tisdale MJ
Br J Cancer; 2005 Feb; 92(4):711-21. PubMed ID: 15714207
[TBL] [Abstract][Full Text] [Related]
58. Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice.
Chen MC; Hsu WL; Hwang PA; Chen YL; Chou TC
Oncotarget; 2016 Aug; 7(32):51608-51618. PubMed ID: 27323407
[TBL] [Abstract][Full Text] [Related]
59. Muscle myostatin signalling is enhanced in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bonetto A; Penna F; Reffo P; Bossola M; Bonelli G; Doglietto GB; Baccino FM; Rossi Fanelli F
Eur J Clin Invest; 2008 Jul; 38(7):531-8. PubMed ID: 18578694
[TBL] [Abstract][Full Text] [Related]
60. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats.
Llovera M; Carbó N; García-Martínez C; Costelli P; Tessitore L; Baccino FM; Agell N; Bagby GJ; López-Soriano FJ; Argilés JM
Biochem Biophys Res Commun; 1996 Apr; 221(3):653-5. PubMed ID: 8630016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
